Mode
Text Size
Log in / Sign up

Diagnostic accuracy study compares HSV-1 IgG assays in adult male workers in Qatar

Diagnostic accuracy study compares HSV-1 IgG assays in adult male workers in Qatar
Photo by Logan Voss / Unsplash
Key Takeaway
Consider the Mindray CLIA for HSV-1 IgG testing, but confirm with a reference standard to minimize misclassification.

This is a diagnostic accuracy study assessing three HSV-1 IgG assays—Mindray CL-900i CLIA, HerpeSelect ELISA, and NovaLisa ELISA—against a Euroimmun Western blot reference standard. The scope was to evaluate seroprevalence and diagnostic performance using 400 archived serum samples from an adult male craft and manual worker cohort in Qatar.

The authors found comparable HSV-1 IgG seroprevalence across all assays: HerpeSelect 72.5%, Mindray 70.5%, NovaLisa 66.3%, and Western blot 66.5%, with all p > 0.05 indicating no statistically significant differences. The Mindray CLIA demonstrated the highest diagnostic performance, with sensitivity 95.7%, specificity 88.9%, accuracy 93.4%, and a kappa of 0.85, indicating strong agreement with the reference standard. HerpeSelect ELISA showed substantial agreement (kappa = 0.81), while NovaLisa ELISA had lower specificity.

The study did not report follow-up duration, safety events, or funding conflicts. Limitations include the single-cohort design and use of archived samples, which may limit generalizability. The authors note that confirmatory testing remains important to minimize misclassification, and the CLIA platform may support high-throughput settings.

Study Details

EvidenceLevel 5
PublishedApr 2026
View Original Abstract ↓
Introduction: Herpes simplex virus type 1 (HSV-1) is highly prevalent worldwide, making accurate serological testing essential for both clinical diagnosis and epidemiological surveillance. Automated chemiluminescent immunoassays (CLIAs) offer operational advantages over enzyme-linked immunosorbent assays (ELISAs); however, their diagnostic performance relative to Western blot (WB) confirmation in high-prevalence settings remains insufficiently characterized. Hypothesis/Gap Statement: The comparative diagnostic accuracy of CLIA- and ELISA-based assays for HSV-1 IgG detection, when benchmarked against a WB reference standard in endemic populations, remains unclear. Aim: This study aimed to evaluate HSV-1 IgG seroprevalence and diagnostic performance of one CLIA and two ELISA platforms using Western blot as the reference method. Methodology: Four hundred archived serum samples from adult male craft and manual workers in Qatar were tested using the Mindray CL-900i CLIA, HerpeSelect ELISA, NovaLisa ELISA, and Euroimmun Western blot. Seroprevalence, diagnostic accuracy, and interassay agreement were assessed using WB as the reference standard, with equivocal and indeterminate results excluded from analysis. Results: HSV-1 IgG seroprevalence estimates were comparable across assays: HerpeSelect 72.5%, Mindray 70.5%, NovaLisa 66.3%, and Western blot 66.5%, with no statistically significant differences (all p > 0.05). The Mindray CLIA demonstrated the highest diagnostic performance (sensitivity 95.7%, specificity 88.9%, accuracy 93.4%) and strong agreement with Western blot ({kappa} = 0.85). HerpeSelect showed substantial agreement ({kappa} = 0.81), while NovaLisa exhibited lower specificity. Conclusion: CLIA- and ELISA-based assays produced comparable HSV-1 seroprevalence estimates in this high-prevalence population; however, diagnostic accuracy varied across platforms. The CLIA platform demonstrated the strongest agreement with Western blot, supporting its use in high-throughput settings, while confirmatory testing remains important to minimize misclassification.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.